01603 327 053
Practitioners
Patients
- Genotyping
State-of-the-art genotyping services - Pharmacogenetics
Personalised approach to prescribing medications - Metagenomic Sequencing
Profiling of gut, oral and vaginal microbiome - Bloodborne Infection Screening
Detection of key blood-borne infections. - Contract Research
Tailored solutions support for the entire assay lifecycle
Treating Mood and Anxiety with Sertraline
When a patient asks, “Is sertraline the right antidepressant for me?”, the most reliable answer may come not from trial and error—but from a pharmacogenomic test. Sertraline is a widely prescribed SSRI (selective serotonin reuptake inhibitor) used across the NHS to treat depression, anxiety, PTSD, and OCD. But what makes it different from other SSRIs? And could it be more effective—or less tolerable—for certain patients?
As UK clinicians increasingly explore pharmacogenomics (PGx), especially for mental health prescribing, it’s worth revisiting sertraline’s unique profile and the role of genetic testing in guiding treatment.
What Makes Sertraline Different?
While all SSRIs boost serotonin, sertraline also influences dopamine, giving it a slightly more activating profile. This makes it especially suitable for patients with:
- Low energy
- Reduced motivation
- Flattened affect
On the other hand, it may not be the best choice in patients with high anxiety or agitation, where its dopaminergic effects could exacerbate symptoms. Another key strength of sertraline is its low interaction potential—a safer choice in polypharmacy or cardiac patients, and those recovering from cardiac events.
Sertraline and Cardiovascular Health
Sertraline is considered one of the safest SSRIs for patients with underlying heart conditions. It is less likely to prolong the QT interval than drugs like citalopram, and has been used successfully in post-myocardial infarction settings.
Recent studies also show that SSRIs may reduce inflammation—a key bridge between chronic stress, depression, and cardiovascular outcomes. Among them, sertraline stands out for its minimal drug–drug interaction risk and favourable side effect profile in cardiac patients.
Side Effects: Why PGx Testing Matters
Despite its generally good tolerability, sertraline isn’t risk-free. Side effects can include:
- Diarrhoea (more common with sertraline than other SSRIs)
- Anxiety (especially at the start of treatment)
- Sedation at higher doses
- QT prolongation in vulnerable individuals
- Rare complications like serotonin syndrome or hyponatraemia
The CYP2C19 and CYP2D6 genes play a key role in metabolising sertraline. Genetic variation in these enzymes helps explain why one patient may thrive while another struggles—even on the same dose. Pharmacogenomic testing can:
- Predict who will need a lower or higher dose
- Flag patients at risk of side effects like QT prolongation
- Reduce delays in symptom relief by skipping ineffective options
How the Body Processes Sertraline: Not One-Size-Fits-All
Sertraline is slowly absorbed, with peak levels reached in 4–10 hours. Taking it with food can increase absorption by 25%, although this isn’t always clinically significant.
Once absorbed, it is metabolised primarily by CYP2C19 and CYP2D6, with secondary roles for CYP3A4/5. Its half-life is long—24 to 32 hours—but blood levels vary significantly between individuals, even at the same dose.
This unpredictable dose–response relationship makes it a prime candidate for personalisation via PGx testing.
Who Should You Test?
Genetic testing is especially helpful in patients who:
- Report side effects or sensitivity to multiple SSRIs
- Have comorbidities or are on multiple medications
- Have cardiac risk factors, where QT monitoring is critical
- Are experiencing treatment-resistant depression or anxiety
In the UK, patients and clinicians can now access saliva-based pharmacogenomic tests through services like AttoDiagnostics. If you’ve searched for “PGx testing near me” or “UK pharmacogenomics”, chances are you’re already seeing this shift toward more personalised prescribing.
Alternatives and Related Medications
Other SSRIs affected by CYP2C19 or CYP2D6 include:
- Citalopram – closely related, but with higher QT risk
- Escitalopram – similar metabolism, often better tolerated
- Paroxetine – more influenced by CYP2D6, higher side effect burden
- Amitriptyline – a tricyclic affected by both genes, useful in mixed mood/pain cases
Pharmacogenomic testing can help narrow the field, reducing the trial-and-error process and supporting more confident decision-making.
Is Sertraline the Best SSRI?
It depends on the patient’s symptom profile, comorbidities, and genetics. In the right context, sertraline offers a compelling balance of efficacy, tolerability, and cardiac safety. But it’s not the best option for everyone.
With pharmacogenomic testing now readily available in the UK, clinicians can go beyond guidelines and start prescribing based on how each patient actually metabolises the medication—not just how it works in theory.